Locally advanced or metastatic solid tumor with KRAS G12D mutation.
For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome.
Cohort specific requirements aas defined in the protocol.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
You may not be if
Prior treatment with any KRAS G12D inhibitor
Known additional invasive malignancy within 1 year of the first dose of study drug
History of organ transplant, including allogeneic stem cell transplantation
